{
  "meta": {
    "title": "Heart_Failure_Part_2",
    "url": "https://brainandscalpel.vercel.app/heart-failure-part-2-5212c15e.html",
    "scrapedAt": "2025-11-30T11:13:02.265Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Improve clinical symptoms and reduce hospitalization.</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Risks more than benefits</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">No role as it is useful only in HF with preserved EF</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Diuretics and ACE inhibitors are better options</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 55-year-old man presents with acute onset shortness of breath. He had a similar episode one month ago, for which he received injections as an outpatient. On examination, his BP is 140/88 mmHg, pulse is 108/min, and oxygen saturation is 97% on room air. Auscultation reveals bilateral basal crepitations. A 2D echocardiogram shows an ejection fraction of 20%, and NT-proBNP > 2000 pg/mL. A diagnosis of heart failure with reduced ejection fraction (HFrEF) is made. What is the ideal role of the sacubitril-valsartan combination in this patient?</span></p>",
      "unique_key": "DT1193041",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193041,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Sacubitril-valsartan</strong> is an <strong>angiotensin receptor-neprilysin inhibitor (ARNI)</strong> indicated for patients with <strong>heart failure with reduced ejection fraction (HFrEF)</strong> to <strong>reduce symptoms, hospitalizations, and mortality</strong>.</p>\n<ul>\n<li><strong>Sacubitril</strong> is a pro-drug that inhibits neprilysin, an enzyme that degrades natriuretic peptides (ANP, BNP), bradykinin, and other vasoactive peptides. Inhibition of neprilysin leads to <strong>increased levels of beneficial natriuretic peptides</strong>, resulting in <strong>vasodilation, natriuresis, diuresis, and reduced cardiac remodeling</strong>.</li>\n<li><strong>Valsartan</strong>, an ARB, is combined with sacubitril to counteract the increased angiotensin II levels caused by neprilysin inhibition.</li>\n<li>Sacubitril-valsartan is preferred over ACE inhibitors in <strong>symptomatic HFrEF (EF &lt; 40%)</strong> as it provides <strong>greater reductions in hospitalization and mortality</strong>.\n<ul>\n<li><strong>Note:</strong> It should not be used with ACE inhibitors due to <strong>risk of angioedema</strong>, and a <strong>36-hour washout period</strong> is necessary when switching from an ACE inhibitor to ARNI.</li>\n</ul>\n</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Risks more than benefits (Option B): </strong>Sacubitril-valsartan is <strong>well tolerated</strong> and shown to have <strong>greater benefit than ACEI alone</strong>, with a <strong>favorable safety profile</strong> when used correctly.</p>\n<p><strong>No role as it is useful only in HF with preserved EF (Option C): </strong>The <strong>strongest evidence and indication</strong> for sacubitril-valsartan is in <strong>HFrEF (EF &le;40%)</strong>, not HFpEF. In HFpEF, benefit is modest and still under investigation.</p>\n<p><strong>Diuretics and ACE inhibitors are better options (Option D): </strong>While <strong>diuretics</strong> help relieve symptoms, they do not modify long-term mortality. <strong>Sacubitril-valsartan is superior to ACE inhibitors</strong> in HFrEF and is now recommended as a <strong>preferred alternative</strong>.</p>",
      "correct_choice_id": 1,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">Neprilysin inhibition and Angiotensin 2 type I receptor blocker</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">Neprilysin inhibition and Angiotensin 2 type 2 receptor blocker</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">Angiotensin 1 receptor blocker and neprilysin inhibitor</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">Neprilysin inhibitor and no effect on angiotensin receptorD)\tNeprilysin inhibitor and no effect on angiotensin receptor</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 46-year-old woman presents for a routine follow-up. She was diagnosed with heart failure with reduced ejection fraction (HFrEF) one month ago. Her medications include a beta-blocker, an ARB, a diuretic, and a sacubitril-valsartan combination. She reports improvement in symptoms. By what mechanism does sacubitril-valsartan work?</span></p>",
      "unique_key": "DT1193044",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193044,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Sacubitril-valsartan</strong> is an <strong>Angiotensin Receptor Neprilysin Inhibitor (ARNI)</strong>. It combines:</p>\n<ul>\n<li><strong>Sacubitril:</strong> A <strong>neprilysin inhibitor</strong>. Neprilysin degrades natriuretic peptides (ANP, BNP), bradykinin, and other vasoactive substances. Inhibition leads to <strong>increased levels of natriuretic peptides</strong>, which promote <strong>vasodilation, natriuresis, diuresis, and inhibition of pathological cardiac remodeling</strong>.</li>\n<li><strong>Valsartan:</strong> An <strong>angiotensin II type 1 receptor (AT1) blocker</strong>, which inhibits vasoconstriction and aldosterone secretion mediated by angiotensin II.</li>\n</ul>\n<p>This dual mechanism both enhances <strong>beneficial natriuretic peptide pathways</strong> and <strong>blocks harmful RAAS activation</strong>. It has been shown to <strong>reduce mortality and hospitalization</strong> in HFrEF.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403288acc6a97-7b60-4c71-8993-5fb354194f9b.jpg\">",
      "correct_choice_id": 11,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">Associated with a reduction in cardiovascular deaths and heart failure events</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Useful only in patients with Type 2 diabetes mellitus and heart failure</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Useful only in patients with Type 1 diabetes mellitus and heart failure</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Only beneficial in reducing heart failure events but has no role in reducing cardiovascular deaths</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following about Dapagliflozin in heart failure is true?</span></p>",
      "unique_key": "DT1193047",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193047,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Dapagliflozin</strong>, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, was originally used for glycemic control in diabetes but is now a recognized agent in the treatment of <strong>heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF)</strong>.</p>\n<ul>\n<li>It works by reducing glucose reabsorption in the proximal renal tubules, causing glycosuria and osmotic diuresis, which leads to <strong>decreased preload and afterload</strong>.</li>\n<li>These hemodynamic effects, along with metabolic and anti-inflammatory benefits, lead to <strong>improved cardiac function</strong>.</li>\n<li>Dapagliflozin <strong>lowers </strong>the risk of heart failure hospitalization and<strong> cardiovascular death</strong>, and these benefits are <strong>independent of the patient's diabetic status</strong>. <strong>(Options B &amp; D ruled out)</strong></li>\n<li>Its use is <strong>not recommended in Type 1 diabetes</strong> due to the <strong>risk of euglycemic diabetic ketoacidosis (DKA)</strong>. <strong>(Option C ruled out)</strong></li>\n</ul>",
      "correct_choice_id": 21,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">TIMI score</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">ACC-AHA pooled cohort equation</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">CHA<sub>2</sub>DS<sub>2-</sub>VASc score</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">HAS-BLED score</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 64-year-old female with heart failure is diagnosed with non-valvular atrial fibrillation. Which of the following scores helps in guiding the need for anticoagulant therapy for stroke prevention?</span></p>",
      "unique_key": "DT1193049",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193049,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The <strong>CHA<sub>2</sub>DS<sub>2</sub>-VASc score</strong> is the recommended tool to <strong>assess stroke risk</strong> in patients with atrial fibrillation and guide the initiation of anticoagulation.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/2025092284c00566-fc4d-4669-9bff-9813ea86b5aa.png\">\n<p><strong>Interpretation:</strong></p>\n<ul>\n<li><strong>Score 0:</strong> No anticoagulation needed</li>\n<li><strong>Score 1:</strong> Consider anticoagulation (risk-benefit assessment)</li>\n<li><strong>Score &ge;2:</strong> Anticoagulation strongly recommended</li>\n</ul>\n<p>In this patient: CHF (1 point) + female sex (1 point) = <strong>2 points &rarr; anticoagulation required</strong>.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>TIMI score (Option A):</strong> Used to estimate <strong>14-day mortality and risk of recurrent ischemic events</strong> in patients with <strong>unstable angina/NSTEMI</strong>, not in atrial fibrillation.<strong></strong></p>\n<p><strong>ACC-AHA pooled cohort equation (Option B):</strong> Estimates the <strong>10-year risk of atherosclerotic cardiovascular disease (ASCVD)</strong> (MI, stroke), but not specifically for AF-related stroke risk.<strong></strong></p>\n<p><strong>HAS-BLED score (Option D):</strong> Assesses the <strong>1-year risk of major bleeding</strong> in patients receiving oral anticoagulation. It complements but does not replace CHA<sub>2</sub>DS<sub>2</sub>-VASc.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250922795ab2cc-4f48-466e-b83c-59a0716c5e49.png\">",
      "correct_choice_id": 33,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Sodium nitroprusside</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Furosemide</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Nifedipine</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Atenolol</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 60-year-old man presents to the emergency department with breathlessness, visual blurring, and headaches. During examination, he develops a generalized tonic-clonic seizure. His blood pressure is 240/120 mmHg. Fundoscopy shows retinal hemorrhages and exudates, and the optic disc margin is not visualized.<br> Which of the following medications is the first-line treatment?</span></p>",
      "unique_key": "DT1193051",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193051,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The patient presents with <strong>malignant hypertension </strong>(hypertensive emergency), characterized by <strong>severely elevated BP (&gt;180/120 mmHg)</strong> with <strong>evidence of target organ damage</strong>, such as <strong>encephalopathy (seizure)</strong> and <strong>papilledema (blurred optic disc margin)</strong>.</p>\n<p>First-line management of malignant hypertension requires rapid yet controlled BP reduction using intravenous agents to prevent further organ damage.</p>\n<ul>\n<li><strong>Sodium nitroprusside</strong> is considered one of the first-line drugs due to its <strong>immediate onset (seconds), short half-life (1-2 min)</strong>, and <strong>potent arterial and venous vasodilation</strong>.</li>\n<li>It acts via <strong>release of nitric oxide (NO), which increases cGMP and relaxes vascular smooth muscle</strong>.</li>\n<li>Recommended dose: <strong>25-10 mcg/kg/min IV infusion</strong>, with close BP monitoring.</li>\n</ul>\n<p><strong>Intravenous drugs used for urgent BP reduction in malignant hypertension include:</strong></p>\n<ul>\n<li>Sodium nitroprusside</li>\n<li>Labetalol</li>\n<li>Nitroglycerin</li>\n<li>Nicardipine</li>\n<li>Esmolol</li>\n<li>Hydralazine</li>\n<li>Fenoldopam</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Furosemide (Option B): </strong>While diuretics like furosemide may be adjuncts in fluid overload or pulmonary edema, they are <strong>not first-line for acute BP reduction</strong> in hypertensive emergencies.</p>\n<p><strong>Nifedipine (Option C): Oral or sublingual nifedipine is contraindicated</strong> in hypertensive emergencies due to risk of <strong>uncontrolled BP drop</strong>, which can cause stroke, MI, or renal ischemia.</p>\n<p><strong>Atenolol (Option D): </strong>Atenolol, a beta-blocker, has <strong>slower onset</strong> and is not preferred in hypertensive emergencies compared to agents like labetalol or esmolol.</p>",
      "correct_choice_id": 41,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">At high risk of heart failure (HF) without structural heart disease</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Structural heart disease with prior symptoms of HF</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Structural heart disease with current symptoms of HF</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Structural heart disease without signs or symptoms of HF</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is the accurate description of Stage B heart failure?</span></p>",
      "unique_key": "DT1193052",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193052,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>ACC/AHA has divided heart failure evolution into 4 stages.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240328bd856cff-850f-417c-861c-14986cef92a0.jpg\">\n<p><strong>Reference</strong>: <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK430873/\" target=\"_blank\">Heart Failure (Congestive Heart Failure) - StatPearls - NCBI Bookshelf</a></p>",
      "correct_choice_id": 54,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Stroke volume / Cardiac output</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">End diastolic volume/end systolic volume</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">End diastolic volume/stroke volume</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Stroke volume/end diastolic volume</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 65-year-old patient is investigated for dyspnea and is found to have an ejection fraction (EF) of 45% on echocardiography. How is the left ventricular ejection fraction calculated?</span></p>",
      "unique_key": "DT1193055",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193055,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Ejection fraction (EF) is the percentage of blood ejected by the ventricle relative to the total amount of blood present in the ventricle at the end of diastole. It is calculated as:</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250922e7d089d3-8bd3-414a-8b02-6b56c9fa161d.png\">\n<p>Where:</p>\n<ul>\n<li><strong>Stroke Volume (SV)</strong> = End Diastolic Volume (EDV) - End Systolic Volume (ESV).</li>\n<li>A <strong>normal EF</strong> is typically <strong>&gt;55%</strong>, indicating efficient pumping.</li>\n<li>In this case, an EF of <strong>45%</strong> indicates <strong>mild left ventricular systolic dysfunction</strong>, which falls into the category of <strong>Heart Failure with mildly reduced EF (HFmrEF)</strong>.</li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250922a8364a77-90db-4170-8041-e97eb6e8aed4.png\">",
      "correct_choice_id": 64,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Ivabradine</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Digoxin + Frusemide</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Bosentan</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Nitrates + Hydralazine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In a patient with heart failure who is intolerant of ACE inhibitors/ARBs, which of the following is best suited to provide a survival benefit?</span></p>",
      "unique_key": "DT1193058",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193058,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>In patients with <strong>heart failure with reduced ejection fraction (HFrEF)</strong> who cannot tolerate <strong>ACE inhibitors or ARBs</strong>, the combination of <strong>nitrates and hydralazine</strong> provides a <strong>survival benefit</strong>.</p>\n<ul>\n<li><strong>Hydralazine</strong> acts as an <strong>arterial vasodilator</strong>, reducing afterload, while <strong>nitrates</strong> primarily cause <strong>venodilation</strong>, decreasing preload. The combined effect leads to reduced cardiac workload and improved cardiac output, which is particularly beneficial in HFrEF patients.</li>\n<li>This combination is especially useful in <strong>RAAS blocker intolerance</strong> (e.g., due to renal dysfunction, hyperkalemia, or angioedema).</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Ivabradine (Option A):</strong> Ivabradine selectively inhibits the <strong>funny (If) current</strong> in the SA node, reducing heart rate. It is indicated for <strong>symptomatic HFrEF</strong> (EF &le;35%) with HR &ge;70 bpm despite optimal beta-blocker therapy. However, <strong>it does not replace RAAS blockade</strong> and its primary benefit is <strong>symptomatic improvement and reduced hospitalizations</strong>, not superior survival benefit compared to nitrates + hydralazine.</p>\n<p><strong>Digoxin + Frusemide (Option B):</strong> Both provide <strong>symptomatic relief</strong>. Digoxin improves contractility and decreases hospitalizations, while frusemide provides diuresis. However, <strong>neither agent improves long-term survival</strong>.</p>\n<p><strong>Bosentan (Option C):</strong> It is an <strong>endothelin receptor antagonist</strong> mainly indicated for <strong>pulmonary arterial hypertension</strong>, not for HFrEF, and does not provide survival benefit in systolic heart failure.</p>",
      "correct_choice_id": 74,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Levosimendan</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Milrinone</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Omecantiv mecarbil</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Dobutamine</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following drugs improves myocardial contractility via calcium sensitization of cardiac muscle?</span></p>",
      "unique_key": "DT1193061",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193061,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Levosimendan</strong> is a unique <strong>positive inotropic agent</strong> that enhances myocardial contractility <strong>without increasing intracellular calcium concentrations</strong>, thus avoiding an associated rise in myocardial oxygen demand.</p>\n<ul>\n<li>It acts by <strong>sensitising cardiac troponin C to calcium</strong>, enhancing actin-myosin interaction and contractility in a <strong>calcium-dependent manner</strong>, a mechanism known as <strong>calcium sensitisation</strong>.</li>\n<li>Additionally, levosimendan also opens <strong>ATP-sensitive potassium channels</strong> in vascular smooth muscle, causing <strong>vasodilation</strong>.</li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Milrinone (Option B)</strong> is a <strong>phosphodiesterase-3 (PDE3) inhibitor</strong> that increases intracellular cAMP levels, resulting in increased calcium influx and positive inotropy, not via calcium sensitisation.</p>\n<p><strong>Omecamtiv mecarbil (Option C)</strong> is a <strong>cardiac myosin activator</strong>. It enhances the <strong>efficiency of actin-myosin interaction</strong> and increases contractility <strong>without altering intracellular calcium</strong> levels, but it does not act via calcium sensitisation of troponin C.</p>\n<p><strong>Dobutamine (Option D)</strong> is a <strong>&beta;1-adrenergic agonist</strong>, which increases myocardial contractility by <strong>increasing intracellular cAMP and calcium</strong>, not by calcium sensitisation.</p>",
      "correct_choice_id": 81,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Addition of Perhexiline therapy</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase diuretic dose</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Referral for implantable defibrillator</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Referral for Cardiac resynchronisation therapy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 77-year-old man with a history of ischaemic heart disease presents with shortness of breath and reduced functional capacity, limited to walking around his home. Echocardiography reveals a left ventricular ejection fraction (LVEF) of ~20%. He is already on maximal medical therapy for heart failure. ECG shows sinus rhythm with a heart rate of 75/min and widened QRS complexes (QRS: 160 ms). What is the most appropriate treatment option at this stage?</span></p>",
      "unique_key": "DT1193062",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193062,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This patient has <strong>heart failure with reduced ejection fraction (HFrEF)</strong>, with an <strong>LVEF of ~20%</strong>, classified as <strong>NYHA Class III</strong> based on limited activity tolerance. He is already on <strong>optimal guideline-directed medical therapy</strong> (GDMT).</p>\n<p>The presence of <strong>widened QRS complex (160 ms)</strong>, most often associated with <strong>left bundle branch block (LBBB)</strong>, indicates <strong>ventricular dyssynchrony</strong>, which contributes to poor systolic function and worsened heart failure symptoms.</p>\n<p>In such patients, <strong>Cardiac Resynchronisation Therapy (CRT)</strong>, also called <strong>biventricular pacing</strong>, has been shown to:</p>\n<ul>\n<li>Improve ventricular synchrony</li>\n<li>Increase cardiac output</li>\n<li>Reduce hospitalisations</li>\n<li>Improve mortality and quality of life</li>\n</ul>\n<p><strong>Indications for CRT include:</strong></p>\n<ul>\n<li>LVEF &le;35%</li>\n<li>Sinus rhythm</li>\n<li>QRS &ge;150 ms (especially with LBBB morphology)</li>\n<li>NYHA Class II-IV symptoms despite optimal therapy</li>\n</ul>\n<p>This patient meets all of the above.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Addition of Perhexiline therapy (Option A): </strong>Perhexiline is a metabolic modulator with limited use and <strong>not part of standard HF therapy</strong>. Its role is investigational and restricted due to hepatotoxicity and neuropathy.</p>\n<p><strong>Increase diuretic dose (Option B): </strong>Diuretics are used for <strong>symptomatic relief</strong> of congestion but do <strong>not improve mortality or reverse cardiac remodeling</strong>. This patient is already on optimal therapy and symptomatic despite it.</p>\n<p><strong>Referral for implantable defibrillator (Option C): </strong>While an <strong>ICD</strong> may be indicated for primary prevention in HFrEF (LVEF &lt;35%), CRT is prioritized here because of <strong>ventricular dyssynchrony (QRS &ge;150 ms)</strong>. ICDs do not improve mechanical efficiency of the heart.</p>",
      "correct_choice_id": 94,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Acanthosis nigricans</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">Fluid retention</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Lactic acidosis</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Myositis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 50-year-old man with an 8-year history of type 2 diabetes mellitus is currently being treated with metformin 1 g twice daily and gliclazide 80 mg daily. He is obese, has gained weight over the last year, and his HbA1c has worsened from 7.5% to 7.9%. His physician decides to discontinue gliclazide and initiate pioglitazone. Which of the following is a typical side effect of pioglitazone therapy?</span></p>",
      "unique_key": "DT1193064",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193064,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Pioglitazone</strong> is a thiazolidinedione (TZD) and functions as a <strong>PPAR-&gamma; agonist</strong>, enhancing insulin sensitivity in adipose tissue, skeletal muscle, and the liver. While effective in glycemic control, its <strong>side-effect profile</strong> is well known and limits its use in certain populations.</p>\n<p>A <strong>typical and common adverse effect</strong> of pioglitazone is <strong>fluid retention</strong>, which occurs in up to 10% of patients. This may manifest as peripheral edema and can exacerbate or precipitate <strong>congestive heart failure</strong>. Therefore, pioglitazone is <strong>contraindicated in NYHA class III-IV heart failure</strong>.<br /> Fluid retention risk increases when used concurrently with agents like <strong>calcium channel blockers</strong>.</p>\n<p>Other notable adverse effects include:</p>\n<ul>\n<li><strong>Weight gain</strong></li>\n<li><strong>Reduction in bone mineral density</strong> &rarr; increased fracture risk, especially in postmenopausal women</li>\n<li><strong>Macular edema</strong> (hence contraindicated in severe diabetic retinopathy)</li>\n<li><strong>Hematocrit reduction</strong> due to hemodilution</li>\n<li><strong>Potential risk of bladder cancer</strong></li>\n</ul>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Acanthosis nigricans (Option A)</strong> is a <strong>clinical marker of insulin resistance</strong>, not a side effect of pioglitazone. In fact, pioglitazone improves insulin sensitivity and may reduce acanthosis nigricans.</p>\n<p><strong>Lactic acidosis (Option C)</strong> is a rare but serious complication associated with <strong>metformin</strong>, not pioglitazone.</p>\n<p><strong>Myositis (Option D) </strong>is more typically seen with <strong>statins</strong>, especially in combination with fibrates. Pioglitazone is not commonly associated with muscle inflammation.</p>",
      "correct_choice_id": 102,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Fatigue</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Syncope</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Palpitation</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Dyspnea</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not a component assessed in NYHA functional classification in heart failure?</span></p>",
      "unique_key": "DT1193067",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193067,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The <strong>New York Heart Association (NYHA) Functional Classification</strong> is a widely used system to categorize <strong>heart failure severity</strong> based on the <strong>degree of functional limitation during physical activity</strong>.</p>\n<p>The symptoms evaluated in this classification include:</p>\n<ul>\n<li>Fatigue <strong>(Option A ruled out)</strong></li>\n<li>Dyspnea <strong>(Option D ruled out)</strong></li>\n<li>Palpitations <strong>(Option C ruled out)</strong></li>\n<li>Angina</li>\n</ul>\n<p>These symptoms are used to determine how heart failure impacts daily physical activities.</p>\n<p><strong>Syncope</strong>, although a serious cardiovascular symptom, is <strong>not included</strong> in the NYHA classification criteria. It is typically evaluated separately as part of investigations into <strong>arrhythmias, structural heart disease, or neurocardiogenic causes</strong>.</p><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250922ac2bceb2-e18c-46ad-a6d3-8c98cc628f01.png\">",
      "correct_choice_id": 112,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduce myocardial oxygen consumption</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduces both preload and afterload</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduce heart rate by inhibiting funny currents in SA node</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Increase cardiac contractility</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following best describes the mechanism with which beta blockers improve outcomes in HFrEF?</span></p>",
      "unique_key": "DT1193068",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193068,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Beta blockers</strong> are a cornerstone in the management of <strong>HFrEF (Heart Failure with Reduced Ejection Fraction)</strong> and have been proven to improve <strong>mortality and morbidity</strong> in several landmark trials, including <strong>COPERNICUS, MERIT-HF, and CIBIS-II</strong>.</p>\n<p>Their primary mechanism involves:</p>\n<ul>\n<li><strong>Decreasing heart rate</strong></li>\n<li><strong>Reducing myocardial contractility</strong></li>\n<li><strong>Blunting sympathetic nervous system</strong> overactivity that contributes to disease progression</li>\n</ul>\n<p>By reducing both <strong>heart rate and contractility</strong>, beta blockers <strong>lower myocardial oxygen consumption</strong>, which leads to <strong>improved energy efficiency</strong>, reduced ischemia, and attenuation of harmful neurohormonal activation. Over time, this results in <strong>reverse remodeling</strong> of the heart and improved systolic function.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Reduces both preload and afterload (Option B): </strong>This describes the action of <strong>ACE inhibitors or nitrates</strong>, not beta blockers. Beta blockers do not significantly affect preload or afterload directly.</p>\n<p><strong>Reduce heart rate by inhibiting funny currents in SA node (Option C): </strong>This is the <strong>mechanism of ivabradine</strong>, not beta blockers. Ivabradine selectively inhibits the <strong>If (funny) current</strong> in the SA node.</p>\n<p><strong>Increase cardiac contractility (Option D): </strong>Beta blockers initially <strong>reduce</strong> contractility. Over time, through reverse remodeling and decreased workload, <strong>cardiac output may improve</strong>, but this is <strong>not due to direct inotropic effects</strong>.</p>",
      "correct_choice_id": 121,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">Acarbose</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">Glipizide</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Nateglinide</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Rosiglitazone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 77-year-old male with type 2 diabetes mellitus requires improved glycaemic control. He also has heart failure which is currently controlled with diuretics and ACE inhibitors. Which of the following hypoglycaemic agents is contraindicated in this patient?</span></p>",
      "unique_key": "DT1193070",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193070,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Rosiglitazone</strong>, a thiazolidinedione (TZD), improves insulin sensitivity by activating PPAR-&gamma; receptors, particularly in adipose tissue. However, <strong>its use is contraindicated in patients with heart failure</strong>, especially NYHA Class III or IV.</p>\n<ul>\n<li><strong>Mechanism of harm:</strong> Rosiglitazone can cause <strong>fluid retention of unclear etiology</strong>, which may precipitate or worsen <strong>congestive heart failure (CHF)</strong>.</li>\n<li>Associated effects include:\n<ul>\n<li><strong>Dilutional anaemia</strong> (&darr;Hb by 1-2 g/dL)</li>\n<li><strong>Peripheral oedema</strong>, particularly <strong>ankle swelling</strong></li>\n</ul>\n</li>\n<li>It is also <strong>contraindicated in hepatic impairment</strong>, as liver metabolism is required for drug clearance.</li>\n<li>Due to these adverse cardiovascular outcomes, rosiglitazone carries a <strong>black box warning</strong> by the FDA regarding heart failure risk.</li>\n</ul>\n<p>Thus, in a diabetic elderly male with established <strong>heart failure</strong>, rosiglitazone is <strong>absolutely contraindicated</strong>.</p>\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Acarbose (Option A) </strong>is an <strong>alpha-glucosidase inhibitor</strong> that delays carbohydrate absorption in the gut. It is <strong>weight-neutral</strong>, does <strong>not cause hypoglycaemia</strong>, and is <strong>safe in heart failure</strong>. GI side effects (flatulence, bloating) are its main limitations.</p>\n<p><strong>Glipizide (Option B) </strong>is a <strong>second-generation sulfonylurea</strong> that increases insulin secretion. It can cause <strong>hypoglycaemia</strong>, especially in the elderly, but is <strong>not contraindicated in CHF</strong>. Caution is required if there is significant renal impairment.</p>\n<p><strong>Nateglinide (Option C)</strong> is a <strong>meglitinide</strong> that increases insulin release but has a <strong>shorter half-life</strong> than sulfonylureas. It is useful for <strong>postprandial glucose control</strong> and is <strong>not contraindicated in heart failure</strong>.</p>",
      "correct_choice_id": 134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypocalcemia</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Liver disease</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypokalemia</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyperthyroidism</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Digoxin has a narrow therapeutic index, and various factors can affect its plasma concentration. Which of the following conditions is most likely to increase the risk of digoxin toxicity?</span></p>",
      "unique_key": "DT1193072",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193072,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation</strong></p>\n<p><strong>Digoxin</strong> is a <strong>cardiac glycoside</strong> that exerts positive inotropic effects by inhibiting the <strong>Na<sup><sub>+</sub></sup>/K<sup>+</sup> ATPase pump</strong>, increasing intracellular calcium in cardiac myocytes. However, it has a <strong>narrow therapeutic window</strong>, and several conditions can precipitate toxicity.</p>\n<ul>\n<li><strong>Hypokalemia</strong> is one of the <strong>most important risk factors</strong> for digoxin toxicity.\n<ul>\n<li>Potassium competes with digoxin for binding to Na<sup>+</sup>/K<sup>+</sup> ATPase.</li>\n<li><strong>Low serum potassium</strong> increases digoxin binding to the enzyme, <strong>enhancing its effects and risk of toxicity</strong>, even if serum digoxin levels are within therapeutic range.</li>\n</ul>\n</li>\n<li>Symptoms of digoxin toxicity include <strong>GI disturbances</strong>, <strong>visual changes (e.g., xanthopsia)</strong>, <strong>arrhythmias</strong>, and <strong>CNS symptoms</strong>.</li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509223472ce87-afe9-4b9b-b2cb-2842d4d23109.png\">\n<p><strong>Explanation of Other Options:</strong></p>\n<p><strong>Hypocalcemia (Option A): Hypercalcemia</strong>, not hypocalcemia, increases the risk of digoxin toxicity due to increased intracellular calcium. Hypocalcemia may actually decrease digoxin effects.</p>\n<p><strong>Liver disease (Option B):</strong> Digoxin is primarily excreted by the <strong>kidneys</strong>, not the liver. Hence, liver disease has <strong>minimal impact</strong> on digoxin clearance and toxicity.</p>\n<p><strong>Hyperthyroidism (Option D): </strong>Though hyperthyroidism may <strong>reduce digoxin efficacy</strong> (due to increased metabolic rate), it does <strong>not increase toxicity</strong>. In fact, hypothyroidism may increase serum digoxin levels due to reduced clearance.</p>",
      "correct_choice_id": 143,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">It is released in response to ventricular volume and pressure overload</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Level of NT-proBNP correlate with severity of heart failure</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Levels fall after initiation of definitive therapy for heart failure</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Levels fall in old age and renal dysfunction</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not true regarding NT-proBNP?</span></p>",
      "unique_key": "DT1193078",
      "question_audio": null,
      "question_video": null,
      "map_id": 1193078,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a well-established <strong>biomarker of cardiac stress</strong>, particularly in the diagnosis, monitoring, and prognostication of heart failure.</p>\n<ul>\n<li><strong>Production:</strong> It is released from <strong>ventricular myocytes</strong> in response to <strong>increased wall stress</strong>, due to <strong>volume or pressure overload</strong>. <strong>(Option A ruled out)</strong></li>\n<li><strong>Clinical relevance:</strong> NT-proBNP levels <strong>correlate with the severity of heart failure</strong> and typically <strong>fall in response to effective treatment</strong>, making it a valuable tool to monitor therapeutic response. <strong>(Options B &amp; D ruled out)</strong></li>\n<li>However, <strong>NT-proBNP levels do not fall</strong> in elderly individuals or in renal dysfunction, in fact, <strong>they increase</strong>. This is due to <strong>reduced clearance and comorbid factors</strong> increasing ventricular strain.</li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509227f2f2c93-5c76-4d1b-ae86-b8cb9c362820.png\">\n<p><strong>Conditions causing elevated NT-proBNP (other than heart failure):</strong></p>\n<ul>\n<li>Renal dysfunction</li>\n<li>Old age</li>\n<li>Critical illness</li>\n<li>Anemia</li>\n<li>Hyperthyroidism</li>\n<li>Pulmonary embolism</li>\n<li>Sepsis</li>\n</ul>",
      "correct_choice_id": 154,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}